The Lancet Haematology in conversation with

Episod

• 
  Bethany Samuelson Bannow and Maureen Achebe on classical haematological disease in women 06.08.2026 24min

  Dr Lan-Lan Smith joined the lead author of our latest Commission Dr Bethany Samuelson Bannow and author Dr Maureen Achebe to discuss classical haematological disease in women with Dr Julia Sandrin Gauer from the Intenational Society on Thrombosis and Haemostasis. The podcast was recorded and produced by the ISTH to coincide with the launch of the Commission at the ISTH congress in Paris in July 2026. Click here to read the commission on thelancet.com: https://www.thelancet.com/commissions-do/women-bleeding-thrombosis The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.comFollow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
• 
  Fabio Efficace and Alice Di Rocco on patient-reported outcomes following CAR T-cell therapy 03.07.2026 15min

  Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce. Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00128-6/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.comFollow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
• 
  Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee 04.06.2026 17min

  Dr Carmelo Gurnari joins us to discuss the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee on diagnosis, prevention, treatment, and donor management of donor cell-derived haematological neoplasms after HCT click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00046-3/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.comFollow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
• 
  Penelope Stein on acute prophyria 28.04.2026 16min

  Dr Penelope Stein joins us to discuss the development of new international guidelines for the diagnosis, management, and treatment of the rare, genetically-linked condition, acute prophyria. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00044-X/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.comFollow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
• 
  Marc Riedl on hereditary angioedema 02.04.2026 17min

  Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks. Click here to read the full articles: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext Continue this conversation on social! Follo...
• 
  Julio Delgado and Valentín Ortiz-Maldonado (Spanish version) 05.03.2026 12min

  Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext English version of this podcast: https://www.buzzsprout.com/1564352/episodes/18730659 Continue this conversation on social! Follow us today at...
• 
  Julio Delgado and Valentín Ortiz-Maldonado 05.03.2026 12min

  Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebo...
• 
  Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology 05.02.2026 19min

  Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgr...
• 
  Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE 01.01.2026 9min

  Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00291-1/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup ht...
• 
  Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation 09.12.2025 14min

  Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https:/...
• 
  ASH 2025 Preview - Expert Roundtable 03.12.2025 22min

  Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
• 
  Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia 02.12.2025 24min

  Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://in...
• 
  Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia 03.11.2025 11min

  Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc...
• 
  A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas 15.09.2025 17min

  Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma. Read the Series: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/?dgcid=buzzsprout_ic...
• 
  Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences 05.08.2025 19min

  June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings. Read our conference round-ups here: EHA: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00206-6/fulltext?dgcid=buzzsprout_icw_podcast_Augu...
• 
  Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lympho... 02.07.2025 21min

  Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3...
• 
  A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies 13.06.2025 40min

  With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care. Read the full series here: https://www.thelancet.com/series-do/adverse-events-in-haematology-oncol...
• 
  Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma 29.04.2025 15min

  Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanha...
• 
  Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia 01.04.2025 17min

  Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancet...
• 
  Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe 04.03.2025 27min

  Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv